Equity Profile

ONC

BeOne Medicines AG

Health CareBiotechnology$39.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BeOne Medicines AG is a biotechnology company focused on developing innovative therapies in the healthcare sector. With a market cap of $40 billion, it plays a significant role in addressing unmet medical needs through advanced drug development.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can impact investor sentiment.

$1.63

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ONC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

83%

Avg EPS Surprise

+540.06%

Avg Stock Reaction

+0.16%

Last Quarter Recap

In Q1 2026, BeOne Medicines reported an impressive EPS of $3.24, significantly surpassing estimates. This strong performance led to a positive stock reaction the following day.

Management Promises & Guidance

Continued focus on innovative drug development.
Commitment to expanding market presence.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about BeOne Medicines' upcoming earnings, expecting solid EPS and revenue figures. The company's recent strong performance may set high expectations.

Bull Case

If BeOne beats EPS estimates again, it could signal strong operational momentum and further validate its growth strategy.

Bear Case

Conversely, if the company misses expectations, it may raise concerns about its ability to sustain growth and could lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.63

Earnings per share is a key indicator of profitability and can impact investor sentiment.

Revenue

$1.6B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BeOne Medicines achieve an EPS of at least $1.63?

This figure is crucial as it sets the benchmark for market expectations and reflects the company's profitability.

How does the revenue of $1.6B compare to previous quarters?

Revenue growth is essential for assessing the company's market demand and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BeOne's ability to leverage recent innovations in drug development, leading to stronger-than-expected revenue growth.

Supporting Evidence

Recent performance has shown a consistent ability to exceed EPS estimates.

The options market indicates heightened volatility, suggesting potential for a significant surprise.

The company's commitment to operational efficiency may yield better margins than anticipated.

Key Risk

If revenue growth exceeds $1.7B, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching BeOne's ability to maintain its growth momentum after a series of strong earnings surprises.

Bull Confirmed If

An EPS of $1.80 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.50 would raise concerns about the company's profitability and growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±16.36%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty or anticipation surrounding the earnings report.

Options are pricing ±16.4% while ONC has averaged ±5.2% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (2K)P/C Ratio: 0.50Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BeOne beats expectations, history suggests a potential stock increase of around 5.3%, confirming the company's growth narrative.

In-Line / Cautious

A report that meets expectations could lead to a muted reaction, as investors weigh future growth prospects.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 7.5%, raising concerns about its growth sustainability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in development.
2Any guidance on future revenue projections.
3Insights into market demand for existing products.
4Comments on operational efficiencies and cost management.
5Management's outlook on competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can impact investor sentiment.

$1.63

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ONC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

83%

Avg EPS Surprise

+540.06%

Avg Stock Reaction

+0.16%

Last Quarter Recap

In Q1 2026, BeOne Medicines reported an impressive EPS of $3.24, significantly surpassing estimates. This strong performance led to a positive stock reaction the following day.

Management Promises & Guidance

Continued focus on innovative drug development.
Commitment to expanding market presence.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about BeOne Medicines' upcoming earnings, expecting solid EPS and revenue figures. The company's recent strong performance may set high expectations.

Bull Case

If BeOne beats EPS estimates again, it could signal strong operational momentum and further validate its growth strategy.

Bear Case

Conversely, if the company misses expectations, it may raise concerns about its ability to sustain growth and could lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.63

Earnings per share is a key indicator of profitability and can impact investor sentiment.

Revenue

$1.6B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BeOne Medicines achieve an EPS of at least $1.63?

This figure is crucial as it sets the benchmark for market expectations and reflects the company's profitability.

How does the revenue of $1.6B compare to previous quarters?

Revenue growth is essential for assessing the company's market demand and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BeOne's ability to leverage recent innovations in drug development, leading to stronger-than-expected revenue growth.

Supporting Evidence

Recent performance has shown a consistent ability to exceed EPS estimates.

The options market indicates heightened volatility, suggesting potential for a significant surprise.

The company's commitment to operational efficiency may yield better margins than anticipated.

Key Risk

If revenue growth exceeds $1.7B, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching BeOne's ability to maintain its growth momentum after a series of strong earnings surprises.

Bull Confirmed If

An EPS of $1.80 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.50 would raise concerns about the company's profitability and growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±16.36%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty or anticipation surrounding the earnings report.

Options are pricing ±16.4% while ONC has averaged ±5.2% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (2K)P/C Ratio: 0.50Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BeOne beats expectations, history suggests a potential stock increase of around 5.3%, confirming the company's growth narrative.

In-Line / Cautious

A report that meets expectations could lead to a muted reaction, as investors weigh future growth prospects.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 7.5%, raising concerns about its growth sustainability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in development.
2Any guidance on future revenue projections.
3Insights into market demand for existing products.
4Comments on operational efficiencies and cost management.
5Management's outlook on competitive pressures in the biotechnology sector.